Second transplant as a standard for multiple myeloma
Mené sur 297 patients atteints d'un myélome multiple récidivant, cet essai multicentrique de phase III compare l'efficacité, du point de vue de la durée avant progression de la maladie, et la toxicité d'une combinaison de fortes doses de melphalan avec une greffe autologue de cellules souches en traitement de sauvetage et un traitement à base de cyclophosphamide
Multiple myeloma is an incurable disease. Recent advances in treatment have included improved diagnostic testing for identification of higher-risk disease, and new therapies, including immunomodulatory agents (IMiDs; thalidomide, lenalidomide, and pomalidomide) and proteasome inhibitors (bortezomib and carfilzomib). After induction therapy, autologous hematopoietic stem-cell transplant (ASCT) followed by consolidation and maintenance is part of the continuum of upfront therapy for transplant-eli ...
The Lancet Oncology , commentaire, 2013